ProMIS Neurosciences Inc. (PMN): Total Liabilities
$10.44M
As of 2025-12-31
$7.29M
As of 2026-06-30
+8.1%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.44M | +330.9% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $2.42M | -75.4% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $9.87M | +19.3% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $8.27M | -31.6% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $12.09M | n/a | 2023-03-08, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| ProMIS Neurosciences Inc. (PMN) | 2025-12-31 | $10.44M | +330.9% |
| Soligenix, Inc. (SNGX) | 2025-12-31 | $3.94M | -18.7% |
| Indaptus Therapeutics, Inc. (INDP) | 2024-12-31 | $3.39M | +19.2% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $1.93M | -40.0% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $2.49M | -94.2% |
| Nanoviricides, Inc. (NNVC) | 2025-06-30 | $1.30M | -4.3% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $3.46M | -74.7% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $2.42M | -6.4% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $7.33M | +12.4% |
Compare PMN, SNGX, INDP, ETST side by side · Screen every company in Pharmaceutical Preparations ↗